Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer
NCT ID: NCT03764137
Last Updated: 2025-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1/PHASE2
INTERVENTIONAL
2019-03-14
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
NCT03087071
PET-MRI in Diagnosing Patients With Colon or Rectal Cancer
NCT01807117
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
NCT04587128
Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer
NCT00111761
Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer
NCT03280277
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
[89Zr]Panitumumab-PET/MRI patients
All study patients will receive \[89Zr\]Panitumumab-PET/MRI imaging.
[89Zr]Panitumumab PET-MRI
All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
[89Zr]Panitumumab PET-MRI
All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of colon cancer
* Scheduled to undergo surgical resection
Exclusion Criteria
* Pregnancy
* Inability to lie still for the imaging study
* Weight over 350 lbs., due to the scanner bore size
* Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos)
* Inability to receive Omnipaque (iohexol) iodinated contrast
* Inability to receive glucagon
* Inability to receive Eovist (gadoxetate disodium) gadolinium based contrast agent
* Allergy to contrast imaging agents
* Finding or suspicion of distant metastases on CT
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Alabama at Birmingham
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Suzanne E. Lapi, PhD
Director Cyclotron Facility
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Suzanne Lapi, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Alabama at Birmingham
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
300002089
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.